Skip to main content
. 2017 Jan 19;8(9):15071–15084. doi: 10.18632/oncotarget.14748

Table 3. XAF1 promoter methylation status and IDH1 status in HGG patients.

N XAF1-M% (N) N XAF1-M% (N) N XAF1-M% (N)
All 80 32.5 (26) Grade III 26 69.2 (18) Grade IV 54 14.8 (8)
IDH1wt 60 10.0 (6) IDH1wt 8 0.0 (0) IDH1wt 52 11.5 (6)
IDH1mut 20 100.0 (20) IDH1mut 18 100.0 (18) IDH1mut 2 100.0 (2)
Cases (N) XAF1-M XAF1-UM IDH1mut IDH1wt XAF1-MIDH1mut XAF1-MIDH1wt
Grade III* (26) 18 8 18 8 18 0
Grade IV* (54) 8 46 52 2 2 6
Grade III (18) IDH1mut 18 0 18 0 18 0
Grade III (8) IDH1mut 0 8 0 0 0 8
Grade IV (2) IDH1mut 2 0 2 0 2 0
Grade IV (58) IDH1mut 6 52 0 58 0 6
Recurrent grade III (6) 6 0 6 0 6 0
Recurrent Grade IV (10) 2+ 8 2+ 8 2+ 0

*Histological tumor grading. +derived from OA.